DiabetesSource

Lexicon Pharmaceuticals, Inc. will hold a conference call on Thursday, January 28, 2010 at 11:30 am Eastern Time to discuss its recent top-line Phase 2 clinical results with LX4211, Lexicon's once-per-day, orally-delivered, small molecule drug candidate for the treatment of type 2 diabetes mellitus.

The dial-in number for the conference call is 888-220-1244 (within the US/Canada) or 706-679-5615 (international). The conference ID for all callers is 53373071. Investors can access a live webcast of the call at lexpharma.com. An archived version of the webcast will be available on the website.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for diabetes, autoimmune disease, carcinoid syndrome, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.